- ... TIMI-3 blood flow, ejection fraction, distal embolization, MACE), mortality, safety (coronary dissection, coronary perforation, prolonged procedure time), or ...
- ... coronary intervention or PCI). The varying definitions of MACE included one related to safety only [composite of death, MI, and stent thrombosis ( ... MI were at greater risk of 1-year MACE. However, for the composite of safety and effectiveness endpoints, the risk of 1-year ...
- ... 150-4 D 67 Riot About face for Mace. Nat Safety News 98: 66-8 O 68 "Chemical Mace" ... See also: Breakage and theft) About face for Mace. Nat Safety News 98: 66-8 O 68 Admitting staff ...
- ... 353-4 N 69 Riot About face for Mace. Nat Safety News 98: 66-8 O 68 American Hospital ... Breakage and theft: Key control) About face for Mace. Nat Safety News 98: 66-8 O 68 Admitting staff ...
- NLM Digital Collections - Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis : ...Publication: Boston, MA : Institute for Clinical and Economic Review, December 2 2016... of these events than other drugs. Long-term safety data on all-cause mortality, MACE, malignancy, and serious infections are available for TNF-α agents and ustekinumab but not for the other drugs of interest for this ... on other safety concerns among the biologic agents or in comparison ...
- ... about AZT so far does not meet the ‘safety and | effectiveness standards that must be applied before a drug can be mace™ available. At this time we have no evidence ...
- ... one of these natural learn- ing situations, is mace aware of Tommy's need for a specific goal to encourage him in his school work. The possibility of a post in the Safety Patrol supplies the needed incentive, and with this ...
- ... of gain-of-function alleles on stroke risk. MACE Composite clinical outcomes, often called MACE, were the ... stent thrombosis in patients with ischemic heart disease. MACE Thirty-seven studies reported information on the ability ...
- NLM Digital Collections - Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis : ...Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, August 3, 2018... 0.1 0.3 0 0 0.1 MACE 0.1 0.2 0 NR NR 0.1 Serious Infections 0.1 0.2 0.4 0 0.6 0.3 Long-term Adverse Events from observational studies As expected, there is currently no long-term safety observational data on any of the new agents. ...
- NLM Digital Collections - Insulin degludec (Tresiba??, Novo Nordisk A/S) for the treatment of diabetes : effectiveness, ...Publication: [Boston, MA] : Institute for Clinical and Economic Review, March 14, 2016... 7637 Time to first major September 2016 Cardiovascular Safety of adverse Insulin Degludec Versus Type 2 DM cardiovascular event Insulin Glargine in Age ≥ 50 years (MACE: CVD death, Subjects With Type 2 Known CVD, ...
1,245 results